Table 2 Univariate analysis for OS and... | American Society of Hematology

Table 2

Univariate analysis for OS and PFS after R-CHOP21 in the training and validation DLBCL series

	Training series				Validation series
	HR	LCI	UCI	P	HR	LCI	UCI	P
OS
MLH1 rs1799977 AG/GG	3.23	1.73	6.03	< .001*	2.97	1.42	6.21	.004*
Age > 60 y	2.00	0.95	4.20	.068	3.71	1.29	10.62	.014*
Male	1.59	0.83	3.04	.162	1.69	0.83	3.46	.147
ECOG PS > 1	2.79	1.32	5.92	.007*	1.05	0.41	2.80	.883
Ann Arbor stage III or IV	1.23	0.66	2.30	.515	1.87	0.91	3.87	.088
Bulky	2.92	1.55	5.48	< .001*	1.81	0.86	3.79	.114
Extranodal sites > 1	2.06	1.08	3.92	.027*	2.56	1.22	5.35	.012*
LDH > ULN	2.52	1.35	4.69	.003*	2.77	1.30	5.89	.008*
IPI score	1.54	1.18	2.00	.001*	1.88	1.37	2.58	< .001*
Non-GC phenotype	1.68	0.59	4.36	.352	NA	NA	NA	NA
RDI cyclophosphamide < 90%	1.69	0.91	3.14	.099	NA	NA	NA	NA
RDI doxorubicin < 90%	2.02	1.08	3.78	.028*	NA	NA	NA	NA
Radiotherapy	1.11	0.57	2.16	.749	1.08	0.50	2.37	.830
PFS
MLH1 rs1799977 AG/GG	2.02	1.20	3.38	.007*	1.92	1.09	3.39	.024*
Age > 60 y	1.74	0.97	3.12	.064	2.75	1.28	5.89	.009*
Male	1.35	0.79	2.31	.364	1.34	0.76	2.36	.311
ECOG PS > 1	1.84	0.93	3.64	.081	1.06	0.50	2.85	.863
Ann Arbor stage III or IV	1.91	1.12	3.26	.017*	2.87	1.56	5.30	.001*
Bulky	2.33	1.39	3.91	.001*	1.26	0.67	2.35	.460
Extranodal sites > 1	1.83	1.07	3.15	.028*	2.98	1.64	5.39	< .001*
LDH > ULN	1.91	1.14	3.22	.014*	2.52	1.39	4.55	.002*
IPI score	1.50	1.21	1.86	< .001*	1.85	1.44	2.38	< .001*
Non-GC phenotype	1.05	0.50	2.18	.897	NA	NA	NA	NA
RDI cyclophosphamide < 90%	1.42	0.85	2.37	.183	NA	NA	NA	NA
RDI doxorubicin < 90%	1.47	0.88	2.46	.136	NA	NA	NA	NA
Radiotherapy	.096	0.56	1.72	.963	1.39	0.63	3.08	.406

	Training series				Validation series
	HR	LCI	UCI	P	HR	LCI	UCI	P
OS
MLH1 rs1799977 AG/GG	3.23	1.73	6.03	< .001*	2.97	1.42	6.21	.004*
Age > 60 y	2.00	0.95	4.20	.068	3.71	1.29	10.62	.014*
Male	1.59	0.83	3.04	.162	1.69	0.83	3.46	.147
ECOG PS > 1	2.79	1.32	5.92	.007*	1.05	0.41	2.80	.883
Ann Arbor stage III or IV	1.23	0.66	2.30	.515	1.87	0.91	3.87	.088
Bulky	2.92	1.55	5.48	< .001*	1.81	0.86	3.79	.114
Extranodal sites > 1	2.06	1.08	3.92	.027*	2.56	1.22	5.35	.012*
LDH > ULN	2.52	1.35	4.69	.003*	2.77	1.30	5.89	.008*
IPI score	1.54	1.18	2.00	.001*	1.88	1.37	2.58	< .001*
Non-GC phenotype	1.68	0.59	4.36	.352	NA	NA	NA	NA
RDI cyclophosphamide < 90%	1.69	0.91	3.14	.099	NA	NA	NA	NA
RDI doxorubicin < 90%	2.02	1.08	3.78	.028*	NA	NA	NA	NA
Radiotherapy	1.11	0.57	2.16	.749	1.08	0.50	2.37	.830
PFS
MLH1 rs1799977 AG/GG	2.02	1.20	3.38	.007*	1.92	1.09	3.39	.024*
Age > 60 y	1.74	0.97	3.12	.064	2.75	1.28	5.89	.009*
Male	1.35	0.79	2.31	.364	1.34	0.76	2.36	.311
ECOG PS > 1	1.84	0.93	3.64	.081	1.06	0.50	2.85	.863
Ann Arbor stage III or IV	1.91	1.12	3.26	.017*	2.87	1.56	5.30	.001*
Bulky	2.33	1.39	3.91	.001*	1.26	0.67	2.35	.460
Extranodal sites > 1	1.83	1.07	3.15	.028*	2.98	1.64	5.39	< .001*
LDH > ULN	1.91	1.14	3.22	.014*	2.52	1.39	4.55	.002*
IPI score	1.50	1.21	1.86	< .001*	1.85	1.44	2.38	< .001*
Non-GC phenotype	1.05	0.50	2.18	.897	NA	NA	NA	NA
RDI cyclophosphamide < 90%	1.42	0.85	2.37	.183	NA	NA	NA	NA
RDI doxorubicin < 90%	1.47	0.88	2.46	.136	NA	NA	NA	NA
Radiotherapy	.096	0.56	1.72	.963	1.39	0.63	3.08	.406

LCI indicates 95% lower confidence interval; UCI, 95% upper confidence interval; NA, not applicable; and GC, germinal center.

Significant value.